Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 14.69
NAS:ATHX's Cash-to-Debt is ranked lower than
56% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. NAS:ATHX: 14.69 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ATHX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12  Med: 166.3 Max: No Debt
Current: 14.69
Equity-to-Asset 0.59
NAS:ATHX's Equity-to-Asset is ranked lower than
57% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NAS:ATHX: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ATHX' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.69  Med: 0.67 Max: 1
Current: 0.59
-4.69
1
Interest Coverage N/A
NAS:ATHX's Interest Coverage is ranked lower than
57% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:ATHX: N/A )
Ranked among companies with meaningful Interest Coverage only.
NAS:ATHX' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 9999.5 Max: No Debt
Current: N/A
N/A
No Debt
Piotroski F-Score: 2
Altman Z-Score: -14.92
Beneish M-Score: -3.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -86.62
NAS:ATHX's Operating Margin % is ranked higher than
51% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. NAS:ATHX: -86.62 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ATHX' s Operating Margin % Range Over the Past 10 Years
Min: -1787.55  Med: -399.32 Max: -86.62
Current: -86.62
-1787.55
-86.62
Net Margin % -88.41
NAS:ATHX's Net Margin % is ranked lower than
51% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. NAS:ATHX: -88.41 )
Ranked among companies with meaningful Net Margin % only.
NAS:ATHX' s Net Margin % Range Over the Past 10 Years
Min: -1360.57  Med: -374.33 Max: -88.41
Current: -88.41
-1360.57
-88.41
ROE % -83.23
NAS:ATHX's ROE % is ranked lower than
73% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. NAS:ATHX: -83.23 )
Ranked among companies with meaningful ROE % only.
NAS:ATHX' s ROE % Range Over the Past 10 Years
Min: -176.55  Med: -103.12 Max: -45.44
Current: -83.23
-176.55
-45.44
ROA % -59.73
NAS:ATHX's ROA % is ranked lower than
70% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. NAS:ATHX: -59.73 )
Ranked among companies with meaningful ROA % only.
NAS:ATHX' s ROA % Range Over the Past 10 Years
Min: -99.51  Med: -67.53 Max: -41.79
Current: -59.73
-99.51
-41.79
ROC (Joel Greenblatt) % -781.14
NAS:ATHX's ROC (Joel Greenblatt) % is ranked lower than
57% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. NAS:ATHX: -781.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ATHX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4646.21  Med: -1644.96 Max: -781.14
Current: -781.14
-4646.21
-781.14
3-Year Revenue Growth Rate 69.60
NAS:ATHX's 3-Year Revenue Growth Rate is ranked higher than
91% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. NAS:ATHX: 69.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ATHX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -18.6 Max: 69.6
Current: 69.6
0
69.6
3-Year EBITDA Growth Rate -25.50
NAS:ATHX's 3-Year EBITDA Growth Rate is ranked lower than
77% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NAS:ATHX: -25.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ATHX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -25.5 Max: -10.7
Current: -25.5
3-Year EPS without NRI Growth Rate -30.20
NAS:ATHX's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:ATHX: -30.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ATHX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -30.2 Max: -4.1
Current: -30.2
GuruFocus has detected 3 Warning Signs with Athersys Inc $NAS:ATHX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ATHX's 10-Y Financials

Financials (Next Earnings Date: 2017-06-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ATHX Guru Trades in Q1 2016

Jim Simons 343,034 sh (+204.02%)
» More
Q2 2016

ATHX Guru Trades in Q2 2016

Joel Greenblatt 10,296 sh (New)
Jim Simons 246,534 sh (-28.13%)
» More
Q3 2016

ATHX Guru Trades in Q3 2016

Joel Greenblatt Sold Out
Jim Simons 136,834 sh (-44.50%)
» More
Q4 2016

ATHX Guru Trades in Q4 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ATHX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:CTIX, NAS:NVIV, NAS:OPHT, NAS:VVUS, NAS:CNAT, OTCPK:BNOEF, NAS:MDWD, NAS:APEN, OTCPK:RNUGF, NAS:LPTX, OTCPK:TBGNF, NAS:CDTX, NAS:PSTI, NAS:AGTC, NAS:EGLT, NAS:ZFGN, NAS:CTIC, NAS:PIRS, NAS:EVGN, NAS:MRTX » details
Traded in other countries:4LS.Germany,
Athersys Inc is a biopharmaceutical company developing regenerative medicine. It is engaged in the discovery and development of therapies designed to extend and enhance human life.

Development-stage biotech Athersys is developing therapies for the treatment of serious diseases. Its flagship biologic product MultiStem is manufactured from human stem cells obtained from adult bone marrow and is undergoing testing for heart attack, bone marrow transplant support, stroke, and other conditions. Outside of its stem cell technology, Athersys is also developing several small-molecule candidates for the treatment of obesity and certain neurological conditions.

Ratios

vs
industry
vs
history
PB Ratio 8.81
ATHX's PB Ratio is ranked lower than
81% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. ATHX: 8.81 )
Ranked among companies with meaningful PB Ratio only.
ATHX' s PB Ratio Range Over the Past 10 Years
Min: 0.18  Med: 4.79 Max: 23.38
Current: 8.81
0.18
23.38
PS Ratio 5.51
ATHX's PS Ratio is ranked higher than
69% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. ATHX: 5.51 )
Ranked among companies with meaningful PS Ratio only.
ATHX' s PS Ratio Range Over the Past 10 Years
Min: 1.15  Med: 7.6 Max: 152.38
Current: 5.51
1.15
152.38
Current Ratio 2.37
ATHX's Current Ratio is ranked lower than
69% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. ATHX: 2.37 )
Ranked among companies with meaningful Current Ratio only.
ATHX' s Current Ratio Range Over the Past 10 Years
Min: 0.47  Med: 5.01 Max: 12.58
Current: 2.37
0.47
12.58
Quick Ratio 2.37
ATHX's Quick Ratio is ranked lower than
65% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ATHX: 2.37 )
Ranked among companies with meaningful Quick Ratio only.
ATHX' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 5.01 Max: 12.58
Current: 2.37
0.47
12.58
Days Sales Outstanding 12.58
ATHX's Days Sales Outstanding is ranked higher than
86% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. ATHX: 12.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
ATHX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.03  Med: 45.04 Max: 156.08
Current: 12.58
11.03
156.08

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.00
ATHX's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. ATHX: -7.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ATHX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -298.1  Med: -41 Max: 0
Current: -7
-298.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 14.25
ATHX's Price-to-Net-Cash is ranked lower than
77% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. ATHX: 14.25 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ATHX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.33  Med: 6.57 Max: 19.13
Current: 14.25
0.33
19.13
Price-to-Net-Current-Asset-Value 11.40
ATHX's Price-to-Net-Current-Asset-Value is ranked lower than
75% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. ATHX: 11.40 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ATHX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.32  Med: 6.09 Max: 15.3
Current: 11.4
0.32
15.3
Price-to-Tangible-Book 8.77
ATHX's Price-to-Tangible-Book is ranked lower than
75% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. ATHX: 8.77 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ATHX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.27  Med: 4.78 Max: 11.86
Current: 8.77
0.27
11.86
Price-to-Median-PS-Value 0.73
ATHX's Price-to-Median-PS-Value is ranked higher than
71% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. ATHX: 0.73 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ATHX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.82 Max: 9.88
Current: 0.73
0.2
9.88
Earnings Yield (Greenblatt) % -13.48
ATHX's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. ATHX: -13.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ATHX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -13.89  Med: 206.2 Max: 17247.5
Current: -13.48
-13.89
17247.5

More Statistics

Revenue (TTM) (Mil) $17.35
EPS (TTM) $ -0.17
Beta-0.38
Short Percentage of Float2.29%
52-Week Range $1.02 - 2.90
Shares Outstanding (Mil)109.80

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1 1 159
EPS ($) -0.30 -0.19 0.58
EPS without NRI ($) -0.30 -0.19 0.58
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:ATHX

Headlines

Articles On GuruFocus.com
Athersys Inc. (ATHX) CEO Bokkelen Gil Van buys 10,000 Shares Mar 18 2009 

More From Other Websites
Athersys, Inc. :ATHX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Two New Publications Highlight the Potential for MultiStem® Treatment of Ischemic Stroke Mar 20 2017
ATHERSYS, INC / NEW Financials Mar 16 2017
Athersys, Inc. :ATHX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
ATHERSYS, INC / NEW Files SEC form 10-K, Annual Report Mar 10 2017
Edited Transcript of ATHX earnings conference call or presentation 9-Mar-17 9:30pm GMT Mar 09 2017
Athersys Reports Financial Results for Fourth Quarter, Full Year 2016 Mar 09 2017
ATHERSYS, INC / NEW Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 09 2017
Q4 2016 Athersys Inc Earnings Release - After Market Close Mar 09 2017
Overview of MultiStem® Clinical Trial in Japan Presentation at International Stroke Conference 2017 Feb 23 2017
Athersys to Host Year-End 2016 Financial Results Call Feb 14 2017
Coverage initiated on Athersys by Needham Feb 07 2017
Athersys Announces Closing of Public Offering of Common Stock Feb 01 2017
ATHERSYS, INC / NEW Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 01 2017
Athersys, Inc. (ATHX) Down, Maybe An Opportunity? Jan 31 2017
Athersys Launches $20M Public Stock Offering Jan 30 2017
Athersys Announces Pricing of Public Offering of Common Stock Jan 27 2017
Athersys Announces Proposed Public Offering of Common Stock Jan 26 2017
Athersys Subsidiary and Leading Animal Health Company Enter Into Research and Option Agreement for... Jan 18 2017
ATHERSYS, INC / NEW Files SEC form 8-K, Change in Directors or Principal Officers Jan 13 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)